Sutro Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Sutro Biopharma

10/08/2023 23:24

* Sutro Biopharma Inc  STRO.OQ  reported a quarterly
adjusted loss
of 64 cents​​ per share for the quarter ended in June. The mean
expectation of eight analysts for the quarter was for a loss
of 73 cents per share.
    * Revenue fell 62.9% to $10.41 million from a year ago;
analysts
expected $12.56 million. 
    * Sutro Biopharma Inc's reported EPS for the quarter was a
loss
of 64 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Sutro Biopharma Inc shares had fallen by 9.2% this
quarter and
lost 47.8% so far this year.
    * The company reported a quarterly loss of $38.52 million.
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 10:24 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.73          -0.64          Beat
 Mar. 31 2023      -0.81          -0.85          Missed
 Dec. 31 2022      -0.62          -0.68          Missed
 Sep. 30 2022      -0.74          -0.37          Beat